Welcome to our dedicated page for EXELIXIS SEC filings (Ticker: EXEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Exelixis Inc. filings document regulatory disclosures for a Nasdaq-listed oncology company with common stock trading under EXEL. Recent 8-K reports furnish results of operations, financial-condition updates, corporate updates tied to the cabozantinib franchise and pipeline activity, and board-authorized common stock repurchase programs.
Proxy and governance filings cover director election matters, executive compensation, equity awards and shareholder voting materials. Other current reports document officer appointments, departures and related compensatory arrangements, connecting leadership changes to the company's research, development, legal and corporate functions.
Exelixis EVP of Research and Development Dana Aftab reported an open-market sale of 47,918 shares of common stock at $44.50 per share. After this sale, Aftab directly holds 616,106 shares, which include 414,043 shares tied to unvested RSUs and PSUs.
Aftab also indirectly holds 5,835 shares through the Exelixis 401(k) plan, based on a statement dated February 23, 2026.
EXEL reported an insider sale. Dana T Aftab sold 29,873 common shares on 02/19/2026 for $1,324,867.55. The filing also lists prior issuances of performance shares and restricted stock with dated grants: 20,006 (01/11/2024), 6,385 (08/15/2023), 8,757 (05/15/2023), and 12,770 (09/06/2023).
EXELIXIS, INC. executive vice president of research and development Dana Aftab reported an open-market sale of 29,873 shares of common stock on February 19, 2026 at a price of $44.35 per share. After this sale, Aftab directly holds 664,024 shares of Exelixis common stock.
In addition, Aftab has an indirect holding of 5,835 shares through the Exelixis 401(k) Plan based on a statement dated February 18, 2026. Footnotes also state that 414,043 shares are scheduled to be issued upon vesting of previously granted RSUs and performance stock units.
Exelixis, Inc. director Jack L. Wyszomierski reported option exercises and share sales. On February 18, 2026, he exercised an option for 20,634 shares of common stock, converting an "Option (right to buy)" that had become fully exercisable on May 23, 2019.
On the same date, he sold 99,574 shares of Exelixis common stock at a weighted average price of $44.01 per share, in multiple trades ranging from $43.32 to $44.49, under a pre-established Rule 10b5-1 trading plan adopted on November 19, 2025. After these transactions, he directly owned 279,942 shares of common stock, including 9,812 shares that will be issued upon vesting of restricted stock units.
EXELIXIS, INC. director Julie Smith reported combined option exercises and stock sales. On February 17–18, 2026, she exercised options covering a total of 106,539 shares of common stock at exercise prices of $18.19, $19.39 and $21.69 per share.
Over the same two days she sold 106,539 shares of Exelixis common stock in open-market transactions at prices including $43.33, $44.30 and $44.50 per share, resulting in a net sale position. After these trades she directly owned 20,590 shares of common stock, and a footnote states she also holds 9,812 restricted stock units that will settle into common shares upon vesting.
EXEL affiliate filing a Form 144 to report proposed resale of common stock derived from performance-share awards. The notice lists multiple tranches of performance shares dated 08/03/2022 (6,385), 02/15/2022 (8,986), 02/03/2021 (11,543) and 11/15/2021 (2,959), and identifies Morgan Stanley Smith Barney LLC as the broker-dealer. Timing and cash‑flow treatment are as reported in the notice.
Exelixis, Inc. executive Christopher J. Senner, EVP and CFO, reported net stock sales. On February 13 and 17, 2026, he executed open‑market sales of Exelixis common stock totaling 64,895 shares at prices around $43–$44 per share.
On February 15, 2026, an additional 35,870 shares were disposed of to cover taxes due on previously granted performance‑based restricted stock units, rather than sold for cash. After these transactions, he directly owned 976,092 shares, which include 427,690 shares underlying RSUs and performance stock units, and indirectly held 2,723 shares through the Exelixis 401(k) plan.
Exelixis, Inc. executive Patrick J. Haley, EVP Commercial, reported significant insider share activity. On February 17, 2026, he executed two open-market sales of Exelixis common stock totaling 67,814 shares, with 3,036 shares sold at $43.84 per share and 64,778 shares sold at $43.50 per share.
On February 15, 2026, 31,483 shares were disposed of to cover taxes due upon vesting of performance-based restricted stock units granted on March 4, 2022, after performance criteria were certified on January 16, 2025. Following these transactions, Haley holds 381,908 shares, a figure that includes restricted stock units and performance stock units granted on March 31, 2025, each representing or economically equivalent to one share of common stock.
EXELIXIS, INC. President and CEO Michael Morrissey reported multiple equity transactions in company common stock. He exercised an option for 494,700 shares on February 13, 2026 at a stated exercise price of $21.31 per share, increasing his direct holdings.
To cover the option exercise price and related taxes, 369,606 shares were withheld at $43.92 per share, and a further 120,390 shares were withheld on February 15, 2026 to satisfy tax liabilities after performance-based restricted stock units vested. Morrissey also made bona fide gifts totaling 501,472 shares over February 17–18, 2026, transferring shares to the Morrissey Family Trust, which holds shares as trustees.
A footnote states that 1,454,115 shares of common stock will be issued upon vesting of previously granted RSUs and performance stock units, each representing the right to receive one share of common stock.
Exelixis director Sue Gail Eckhardt reported an open-market sale of 3,856 shares of common stock on February 13, 2026 at a weighted average price of $43.79 per share. The transaction was executed under a prearranged Rule 10b5-1 trading plan adopted on November 11, 2025. After this sale, she beneficially owns 17,524 shares, including shares that will be issued upon vesting of restricted stock units.